Free Trial

Strategic Financial Concepts LLC Acquires Shares of 39,148 Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company logo with Medical background

Strategic Financial Concepts LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 39,148 shares of the medical instruments supplier's stock, valued at approximately $8,882,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tompkins Financial Corp lifted its stake in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 46 shares during the period. Radnor Capital Management LLC lifted its position in Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier's stock worth $708,000 after buying an additional 48 shares during the period. Wesbanco Bank Inc. boosted its stake in Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock worth $580,000 after buying an additional 48 shares during the last quarter. Umpqua Bank grew its holdings in Becton, Dickinson and Company by 1.8% in the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier's stock valued at $660,000 after buying an additional 49 shares during the period. Finally, Americana Partners LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.5% during the 3rd quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier's stock worth $354,000 after acquiring an additional 50 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, February 12th. Piper Sandler upped their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a report on Tuesday, January 28th. Finally, Barclays increased their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $278.29.

Read Our Latest Stock Report on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Up 1.1 %

Becton, Dickinson and Company stock traded up $2.43 during trading on Wednesday, reaching $227.56. 1,072,173 shares of the company's stock were exchanged, compared to its average volume of 2,113,271. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The firm has a market cap of $65.34 billion, a price-to-earnings ratio of 37.80, a PEG ratio of 1.61 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The company's 50-day moving average is $232.72 and its two-hundred day moving average is $233.42.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. Becton, Dickinson and Company's payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its board has authorized a stock buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued.

Insider Activity

In other news, EVP David Shan sold 500 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares of the company's stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,544 shares of company stock worth $2,370,309 over the last ninety days. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Read More

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Should You Invest $1,000 in Becton, Dickinson and Company Right Now?

Before you consider Becton, Dickinson and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.

While Becton, Dickinson and Company currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines